Related Experiment Videos
Generalized peripheral iris transluminance in the pseudoexfoliation syndrome
L P Repo1, M E Teräsvirta, E J Tuovinen
1Department of Ophthalmology, University Central Hospital, Kuopio, Finland.
Ophthalmology
|August 1, 1990
Summary
Pseudoexfoliation syndrome (PXS) significantly alters iris transluminance, with abnormal findings in 45% of affected eyes compared to 18% in controls. This indicates PXS is a key factor affecting iris light transmission.
Area of Science:
- Ophthalmology
- Ocular Physiology
Background:
- Pseudoexfoliation syndrome (PXS) is a common condition affecting ocular tissues.
- Iris transluminance, a measure of light transmission through the iris, has not been extensively studied in PXS.
- Understanding iris abnormalities in PXS is crucial for diagnosing and managing associated ocular conditions.
Purpose of the Study:
- To investigate generalized peripheral iris transluminance in eyes with pseudoexfoliation syndrome (PXS).
- To compare iris transluminance between PXS eyes and control eyes.
- To analyze factors influencing iris transluminance in PXS, including glaucoma, cataracts, and diabetes.
Main Methods:
- Diascleral transillumination was used to assess peripheral iris transluminance.
- The study included 212 eyes with PXS (with or without glaucoma) and 100 control eyes.
- Logistic regression analysis was employed to adjust for confounding factors like age, cataracts, and diabetes.
Main Results:
- Abnormal iris transluminance was observed in 45% of PXS eyes versus 18% of control eyes (P < 0.001).
- The presence of PXS, with or without glaucoma, was a statistically significant factor influencing iris transluminance (P < 0.01) after adjusting for other variables.
- Age, coexisting capsular glaucoma, cataracts, and adult-onset diabetes showed varying degrees of influence.
Conclusions:
- Pseudoexfoliation syndrome is strongly associated with abnormal peripheral iris transluminance.
- Iris transluminance measurement can be a valuable diagnostic aid in identifying PXS.
- Further research may explore the clinical implications of altered iris transluminance in PXS management.